Alere Company Profile (NYSE:ALR)

About Alere (NYSE:ALR)

Alere logoAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:ALR
  • CUSIP: 01449J10
  • Web:
  • Market Cap: $4.34 billion
  • Outstanding Shares: 87,577,000
Average Prices:
  • 50 Day Moving Avg: $50.11
  • 200 Day Moving Avg: $45.67
  • 52 Week Range: $34.41 - $50.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 35.39
  • P/E Growth: 5.320
Sales & Book Value:
  • Annual Revenue: $2.32 billion
  • Price / Sales: 1.87
  • Book Value: $13.20 per share
  • Price / Book: 3.75
  • EBIDTA: $261.2 million
  • Net Margins: -10.73%
  • Return on Equity: 4.54%
  • Return on Assets: 1.01%
  • Debt-to-Equity Ratio: 2.43%
  • Current Ratio: 2.04%
  • Quick Ratio: 1.54%
  • Average Volume: 1.51 million shs.
  • Beta: 0.2
  • Short Ratio: 1.85

Frequently Asked Questions for Alere (NYSE:ALR)

What is Alere's stock symbol?

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

How were Alere's earnings last quarter?

Alere Inc. (NYSE:ALR) announced its quarterly earnings data on Friday, November, 4th. The company reported $0.19 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.54 by $0.35. The firm had revenue of $582 million for the quarter, compared to analysts' expectations of $605.50 million. Alere had a negative net margin of 10.73% and a positive return on equity of 4.54%. The business's quarterly revenue was down 3.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.10) earnings per share. View Alere's Earnings History.

When will Alere make its next earnings announcement?

Alere is scheduled to release their next quarterly earnings announcement on Tuesday, September, 5th 2017. View Earnings Estimates for Alere.

Where is Alere's stock going? Where will Alere's stock price be in 2017?

5 brokerages have issued twelve-month price objectives for Alere's stock. Their forecasts range from $42.00 to $51.00. On average, they anticipate Alere's stock price to reach $48.00 in the next twelve months. View Analyst Ratings for Alere.

What are analysts saying about Alere stock?

Here are some recent quotes from research analysts about Alere stock:

  • 1. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (8/17/2017)
  • 2. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)

Who are some of Alere's key competitors?

Who are Alere's key executives?

Alere's management team includes the folowing people:

  • Gregg J. Powers, Independent Chairman of the Board
  • Namal Nawana, President, Chief Executive Officer, Director
  • James F. Hinrichs, Chief Financial Officer, Executive Vice President
  • Daniella Cramp, Global President - Cardiometabolic Business Unit
  • Sanjay Malkani, Global President - Toxicology
  • Avi Pelossof, Global President - Infectious Disease Business Unit
  • Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
  • Robert Hargadon, Senior Vice President - Global Human Resources
  • John Bridgen Ph.D., Senior Vice President - Business Development
  • Mark Gladwell, Senior Vice President - Global Operations

Who owns Alere stock?

Alere's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.02%), Farallon Capital Management LLC (4.97%), BlackRock Inc. (4.02%), Goldman Sachs Group Inc. (3.19%), Dimensional Fund Advisors LP (3.13%) and Renaissance Technologies LLC (2.55%). Company insiders that own Alere stock include James F Hinrichs, Mark Gladwell, Melissa Guerdan and Robert Bernard Hargadon. View Institutional Ownership Trends for Alere.

Who sold Alere stock? Who is selling Alere stock?

Alere's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Prudential PLC, Cornerstone Capital Management Holdings LLC., Diamond Hill Capital Management Inc., Stonepine Capital Management LLC, New York State Common Retirement Fund, State of New Jersey Common Pension Fund D and BlackRock Inc.. View Insider Buying and Selling for Alere.

Who bought Alere stock? Who is buying Alere stock?

Alere's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Farallon Capital Management LLC, York Capital Management Global Advisors LLC, Cowen Inc., Omni Partners LLP, GLG Partners LP and City Financial Investment Co Ltd. Company insiders that have bought Alere stock in the last two years include James F Hinrichs and Robert Bernard Hargadon. View Insider Buying and Selling for Alere.

How do I buy Alere stock?

Shares of Alere can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alere's stock price today?

One share of Alere stock can currently be purchased for approximately $49.55.

MarketBeat Community Rating for Alere (NYSE ALR)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alere (NYSE:ALR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $48.00 (3.13% downside)

Analysts' Ratings History for Alere (NYSE:ALR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/6/2017Canaccord GenuityDowngradeBuy -> Hold$51.00MediumView Rating Details
6/1/2017Jefferies Group LLCReiterated RatingHold$51.00MediumView Rating Details
5/24/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/15/2017Craig HallumDowngradeBuy -> HoldLowView Rating Details
11/4/2016Goldman Sachs Group, Inc. (The)Lower Price TargetNeutral$45.00 -> $42.00N/AView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$56.00N/AView Rating Details
2/2/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
11/5/2015WedbushLower Price TargetNeutral$43.00 -> $39.00N/AView Rating Details
(Data available from 8/18/2015 forward)


Earnings History for Alere (NYSE:ALR)
Earnings by Quarter for Alere (NYSE:ALR)
Earnings History by Quarter for Alere (NYSE ALR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 16$0.54$0.19$605.50 million$582.00 millionViewN/AView Earnings Details
9/6/2016Q216$0.58($0.46)$621.95 million$611.10 millionViewN/AView Earnings Details
8/17/2016Q116$0.56($0.18)$578.00 millionViewN/AView Earnings Details
8/8/2016Q415$0.58($0.28)$662.04 million$623.00 millionViewN/AView Earnings Details
11/4/2015Q315$0.55$0.49$646.29 million$602.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.53$0.49$625.67 million$629.00 millionViewN/AView Earnings Details
5/5/2015Q115$0.49$0.57$612.93 million$610.40 millionViewN/AView Earnings Details
2/10/2015Q414$0.63$0.61$698.56 million$666.90 millionViewN/AView Earnings Details
10/28/2014Q314$0.52$0.48$743.30 million$736.20 millionViewN/AView Earnings Details
8/4/2014Q214$0.58$0.43$747.55 million$738.30 millionViewN/AView Earnings Details
4/29/2014Q114$0.55$0.55$738.70 million$716.60 millionViewN/AView Earnings Details
2/6/2014Q413$0.56$0.62$770.70 million$772.30 millionViewN/AView Earnings Details
10/29/2013Q313$0.53$0.59$737.66 million$753.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.48$0.64$720.24 million$764.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.51$0.53$727.66 million$739.20 millionViewN/AView Earnings Details
2/15/2013Q4 2012$0.57$0.55$714.75 million$755.80 millionViewN/AView Earnings Details
11/8/2012Q312$0.53$0.43$690.76 million$691.40 millionViewN/AView Earnings Details
8/8/2012$0.53($0.23)ViewN/AView Earnings Details
4/30/2012$0.67$0.77ViewN/AView Earnings Details
2/8/2012$0.71$0.74ViewN/AView Earnings Details
10/26/2011$0.57$0.67ViewN/AView Earnings Details
7/27/2011$0.58$0.46ViewN/AView Earnings Details
4/27/2011$0.61$0.61ViewN/AView Earnings Details
2/17/2011$0.66$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alere (NYSE:ALR)
Current Year EPS Consensus Estimate: $0.93 EPS
Next Year EPS Consensus Estimate: $1.40 EPS


Dividend History for Alere (NYSE:ALR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alere (NYSE:ALR)
Insider Ownership Percentage: 3.66%
Institutional Ownership Percentage: 80.53%
Insider Trades by Quarter for Alere (NYSE:ALR)
Institutional Ownership by Quarter for Alere (NYSE:ALR)
Insider Trades by Quarter for Alere (NYSE:ALR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016Melissa GuerdanSVPSell2,500$54.00$135,000.00View SEC Filing  
11/13/2015Robert Bernard HargadonSVPBuy1,000$38.99$38,990.00View SEC Filing  
11/12/2015James F HinrichsCFOBuy10,000$39.97$399,700.00View SEC Filing  
9/3/2015Mark GladwellVPSell2,651$52.27$138,567.77View SEC Filing  
9/3/2015Melissa GuerdanSVPSell5,135$52.00$267,020.00View SEC Filing  
9/1/2015Melissa GuerdanSVPSell5,000$50.48$252,400.00View SEC Filing  
8/31/2015Mark GladwellVPSell27,513$52.23$1,437,003.99View SEC Filing  
8/14/2015Sanjay MalkaniInsiderSell31,460$54.60$1,717,716.00View SEC Filing  
6/8/2015Sanjay MalkaniInsiderSell24,331$50.87$1,237,717.97View SEC Filing  
6/4/2015Sanjay MalkaniInsiderSell15,669$52.18$817,608.42View SEC Filing  
6/1/2015John BridgenSVPSell7,500$51.19$383,925.00View SEC Filing  
4/6/2015Melissa GuerdanSVPSell2,500$50.00$125,000.00View SEC Filing  
3/23/2015Melissa GuerdanSVPSell13,476$48.35$651,564.60View SEC Filing  
3/17/2015John BridgenSVPSell25,000$48.53$1,213,250.00View SEC Filing  
3/16/2015Carla FlakneCAOSell8,500$48.99$416,415.00View SEC Filing  
1/16/2015Carla FlakneCAOSell10,000$42.45$424,500.00View SEC Filing  
12/24/2014Don DudekDirectorBuy40,000$0.01$500.00
12/11/2014John BridgenSVPSell50,000$37.07$1,853,500.00View SEC Filing  
8/15/2014Dave TeitelCFOSell10,000$35.07$350,700.00View SEC Filing  
8/15/2013Dave TeitelCFOSell10,000$31.73$317,300.00View SEC Filing  
8/5/2013Michael Lester CottonInsiderSell12,500$33.82$422,750.00View SEC Filing  
5/31/2013Michael Lester CottonInsiderSell8,750$25.86$226,275.00View SEC Filing  
3/5/2013John QuelchDirectorSell20,220$23.49$474,967.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alere (NYSE:ALR)
Latest Headlines for Alere (NYSE:ALR)
DateHeadline logoZacks Investment Research Lowers Alere Inc. (ALR) to Sell - August 17 at 4:54 PM logoAlere, Inc. :ALR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 - August 16 at 3:48 PM logoSee what the IHS Markit Score report has to say about Alere Inc. - August 12 at 3:34 PM logoSee what the IHS Markit Score report has to say about Alere Inc. - August 12 at 3:34 PM logoAlere Provides Notice to Holders of Series B Convertible Perpetual Preferred Stock - August 11 at 4:16 PM logoEARNINGS SUMMARY: Details of Alere Inc. Q2 Earnings Report - August 4 at 9:09 PM logoAlere Enters Oversold Territory (ALR) - August 4 at 9:09 PM logoAlere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : August 4, 2017 - August 4 at 4:07 PM logoAlere Reports Second Quarter 2017 Financial Results - August 3 at 4:45 PM logoAlere (ALR) Says Immunalysis Receives FDA Clearance for SEFRIA ... - - July 31 at 3:52 PM logoImmunalysis Receives FDA Clearance for SEFRIA™ Fentanyl Urine Drug Screening Test - July 31 at 3:52 PM logoAlere Inc. (NYSE:ALR) Scheduled to Post Quarterly Earnings on Monday - July 31 at 8:05 AM logoAlere Inc. (NYSE:ALR) Receives Consensus Recommendation of "Hold" from Analysts - July 29 at 7:45 AM logoAbbott deal will cost Alere three business units — and untold employees - Boston Business Journal - July 24 at 11:35 PM logoAbbott deal will cost Alere three business units — and untold employees - July 24 at 6:32 PM logoAbbott CEO: Another Alere-Related Divestiture Coming Soon - - July 20 at 5:09 PM logoAlere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings - - July 20 at 7:01 AM logoAlere Launches Alere iCup® Rx Drug Screen for Detecting Commonly Misused and Abused Prescription Drugs - July 19 at 4:56 PM logoHere's Why Quidel Corporation Is Rising Today - July 19 at 4:56 PM logoAlere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings - July 19 at 4:56 PM logoWall Street's M&A Chatter From July 17: BorgWarner-Sevcon, Church & Dwight-Waterpik, Quidel-Alere Triage - Benzinga - July 18 at 5:15 PM logoAbbott Commences Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. - July 17 at 4:04 PM logoQuidel Corp. (QDEL) Has Jumped To A New High After Acquisition - July 17 at 4:04 PM logoMinuteClinic deal will expand KC screening company's reach by 1,100 sites - July 12 at 9:15 PM logoCritical Review: Koninklijke Philips N.V. (PHG) and Alere (ALR) - July 12 at 7:46 AM logoPro-Trader Daily: Featured Company News - Alere Announces Approval of Amended Merger Agreement by Shareholders with Abbott Labs - July 11 at 10:00 PM logoAlere (ALR) Shareholders Approve Amended Merger with Abott (ABT) - July 8 at 5:04 AM logoHCA Healthcare, Inc. -- Moody's: HCA's Increased ABL Reduces Likelihood of Upgrade of Senior Secured Notes - July 8 at 5:04 AM logoAlere Shareholders Approve Amended Merger with Abbott - July 8 at 5:04 AM logoAlere Shareholders Vote to Approve Amended Merger with Abbott - July 8 at 5:04 AM logoComparing Alere (NYSE:ALR) & IRIDEX Corporation (IRIX) - July 7 at 2:10 PM logoETFs with exposure to Alere, Inc. : July 4, 2017 - July 4 at 5:58 PM logoAlere Inc. (ALR) Given Average Recommendation of "Hold" by Brokerages - July 4 at 10:50 AM logoAlere Inc. (ALR) Sees Significant Increase in Short Interest - July 3 at 7:14 AM logoZacks Investment Research Upgrades Alere Inc. (ALR) to Hold - June 27 at 6:28 PM logoFeatured Company News - PerkinElmer Announces Acquisition of EUROIMMUN; Set To Expand its Autoimmune Testing Portfolio - June 21 at 4:17 PM logoETFs with exposure to Alere, Inc. : June 20, 2017 - June 20 at 4:01 PM logoAlere, Inc. :ALR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 - June 19 at 3:33 PM logoAlere Reports First Quarter 2017 Financial Results - June 14 at 8:34 PM logoAlere reports 1Q loss - June 14 at 8:34 PM logoAlere Inc (ALR) Receives Consensus Rating of "Hold" from Brokerages - June 9 at 11:00 AM logoAlere Inc. (ALR) Jumped To A New High After Q4 Report - June 7 at 8:37 PM logoCramer's lightning round: This downtrodden stock's no more than a value play - June 7 at 8:37 PM logoAlere Inc (ALR) Lowered to Hold at Canaccord Genuity - June 6 at 1:40 PM logoAlere Inc. (ALR) Is Heading Higher Following Q4 Report - June 5 at 6:26 PM logoAlere Files Form 10-K, Reports Fourth Quarter and Full Year 2016 Financial Results - June 5 at 6:26 PM logoAlere Inc. Announces Termination of Consent Solicitations for Alere Inc.'s Notes and Offers Consent Termination Fee - June 5 at 6:26 PM logoAlere reports 4Q loss - June 5 at 6:26 PM logoAlere Inc. Announces Commencement of Additional Consent Solicitations for Alere Inc.'s Notes - June 3 at 2:40 AM logoAlere Inc (ALR) Short Interest Update - June 1 at 7:03 AM



Alere (ALR) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by Staff